The perspectives of survivors of Hodgkin lymphoma on lung cancer screening

A qualitative study

Bibliographic Data

ID19508720
AuthorsRachel Broadbent (0000-0002-1913-3140, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health University of Manchester UK, corresponding author), Louise Gorman (0000-0002-6570-7272, NIHR Greater Manchester Patient Safety Translational Research Centre, Centre for Mental Health and Safety, Division of Population Health, Health Services Research & Primary Care, Faculty of Biology, Medicine and Health University of Manchester Manchester UK), Christopher J Armitage (0000-0003-2365-1765, NIHR Greater Manchester Patient Safety Translational Research Centre University of Manchester Manchester UK), John Radford (0000-0001-7898-2786, Manchester Cancer Research Centre Manchester UK), Kim Linton (0000-0002-3294-1548, Manchester Cancer Research Centre Manchester UK)
Year2022
Volume25
Issue1
Pages116-124
Publication date2022-02-01
Open AccessYes
TypeARTICLE
VenueHealth Expectations (JOURNAL)
Journal identifiersISSN: 1369-6513 • E-ISSN: 1369-7625
PublisherWiley (PUBLISHER • GB)
DOI10.1111/hex.13353
PMID34755419
OpenAlexW3205334649
LanguageEN
Citations received1
References cited37

BACKGROUND: Hodgkin lymphoma survivors (HLS) are at excess risk of lung cancer as a consequence of HL treatment. HLS without a heavy smoking history are currently unable to access lung cancer screening (LCS) programmes aimed at ever smokers, and there is an unmet need to develop a targeted LCS programme. In this study we prospectively explored HLS perspectives on a future LCS programme, including motivating factors and potential barriers to participation, with the aim of identifying ways to optimise uptake in a future programme. METHODS: Semistructured telephone interviews were conducted with HLS, aged 18-80 and lymphoma-free for ≥5 years, selected from a clinical database (ADAPT). Participants provided informed consent. Data were analysed using inductive thematic analysis. RESULTS: Despite awareness of other late effects, most participants were unaware of their excess risk of lung cancer. Most were willing to participate in a future LCS programme, citing the potential curability of early-stage lung cancer and reassurance as motivating factors, whilst prior experience of healthcare was a facilitator. Whilst the screening test (a low dose CT scan) was considered acceptable, radiation risk was a concern for some and travel and time off work were potential barriers to participation. CONCLUSIONS: Our results suggest that most HLS would participate in a future LCS programme, motivated by perceived benefits. Their feedback identified a need to develop educational materials addressing lung cancer risk and concerns about screening, including radiation risk. Such materials could be provided upon an invitation to LCS. Uptake in a future programme may be further optimized by offering flexible screening appointments close to home

Facilitator · Family medicine · Lung cancer · Lung cancer screening · Qualitative research · Thematic analysis · Lung Cancer Diagnosis and Treatment · Lung Cancer Treatments and Mutations · Lymphoma Diagnosis and Treatment · Medicine · Psychology · Social Psychology · Oncology

Tools

Open DOIOpen Access